2012-2022 年挪威儿科人群中出现的 D68 型肠道病毒

IF 2 Q4 VIROLOGY
Elisabeth Toverud Landaas, Ingvild Klundby, Per Kristian Knudsen, Anne-Marte Bakken Kran, Susanne Dudman, Andreas Lind, Mona Holberg-Petersen
{"title":"2012-2022 年挪威儿科人群中出现的 D68 型肠道病毒","authors":"Elisabeth Toverud Landaas, Ingvild Klundby, Per Kristian Knudsen, Anne-Marte Bakken Kran, Susanne Dudman, Andreas Lind, Mona Holberg-Petersen","doi":"10.3389/fviro.2024.1358963","DOIUrl":null,"url":null,"abstract":"<sec><title>Background</title><p>Enterovirus D68 (EV-D68) primarily causes respiratory infection, occasionally manifesting with neurological symptoms. Outbreak reports have been published from various countries including Norway, but a longitudinal study on EV-D68 prevalence in Northern Europe is lacking.</p></sec><sec><title>Methods</title><p>Respiratory samples from children ≤14 years received at Oslo University Hospital in the years 2012-2022 were examined for EV-D68. Samples from 2012-2015 were retrospectively screened using a semi-specific RT-PCR, with positive samples confirmed by an EV-D68 specific RT-PCR. Samples from 2016-2022 underwent routine diagnostics with the EV-D68 specific RT-PCR.</p></sec><sec><title>Results</title><p>Among the 22,911 samples tested, EV-D68 was detected in 338 samples (324 patients). Most EV-D68 cases occurred in August to December. The highest detection rate was recorded in 2014, 2016 and 2022 (6.0%, 7.8% and 6.6% of samples from August-December). Lower frequencies were observed in 2018 and 2019 (1.0% and 2.4%), and in the years before the 2014 outbreak (2012: 1.3%, 2013: 0.8%). Few cases were identified in 2020-2021. Children aged 0-1 years accounted for 40%, and 0-4 years for 78%, of the EV-D68 positive patients. Most of the patients with EV-D68 (83%) were hospitalised.</p></sec><sec><title>Discussion</title><p>Also in Norway, EV-D68 has caused outbreaks with significant disease burden, especially among the youngest children. The detection rate varies, with a trend towards biennial outbreaks, except for low numbers in 2018 and during the COVID-19 restrictions (2020-2021). Due to its potential for severe respiratory illness and significant neurological complications, conducting EV-D68 testing is essential both for diagnosing clinically suspected cases, and for monitoring the disease burden.</p></sec>","PeriodicalId":73114,"journal":{"name":"Frontiers in virology","volume":"11 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emergence of enterovirus D68 in a Norwegian paediatric population 2012-2022\",\"authors\":\"Elisabeth Toverud Landaas, Ingvild Klundby, Per Kristian Knudsen, Anne-Marte Bakken Kran, Susanne Dudman, Andreas Lind, Mona Holberg-Petersen\",\"doi\":\"10.3389/fviro.2024.1358963\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<sec><title>Background</title><p>Enterovirus D68 (EV-D68) primarily causes respiratory infection, occasionally manifesting with neurological symptoms. Outbreak reports have been published from various countries including Norway, but a longitudinal study on EV-D68 prevalence in Northern Europe is lacking.</p></sec><sec><title>Methods</title><p>Respiratory samples from children ≤14 years received at Oslo University Hospital in the years 2012-2022 were examined for EV-D68. Samples from 2012-2015 were retrospectively screened using a semi-specific RT-PCR, with positive samples confirmed by an EV-D68 specific RT-PCR. Samples from 2016-2022 underwent routine diagnostics with the EV-D68 specific RT-PCR.</p></sec><sec><title>Results</title><p>Among the 22,911 samples tested, EV-D68 was detected in 338 samples (324 patients). Most EV-D68 cases occurred in August to December. The highest detection rate was recorded in 2014, 2016 and 2022 (6.0%, 7.8% and 6.6% of samples from August-December). Lower frequencies were observed in 2018 and 2019 (1.0% and 2.4%), and in the years before the 2014 outbreak (2012: 1.3%, 2013: 0.8%). Few cases were identified in 2020-2021. Children aged 0-1 years accounted for 40%, and 0-4 years for 78%, of the EV-D68 positive patients. Most of the patients with EV-D68 (83%) were hospitalised.</p></sec><sec><title>Discussion</title><p>Also in Norway, EV-D68 has caused outbreaks with significant disease burden, especially among the youngest children. The detection rate varies, with a trend towards biennial outbreaks, except for low numbers in 2018 and during the COVID-19 restrictions (2020-2021). Due to its potential for severe respiratory illness and significant neurological complications, conducting EV-D68 testing is essential both for diagnosing clinically suspected cases, and for monitoring the disease burden.</p></sec>\",\"PeriodicalId\":73114,\"journal\":{\"name\":\"Frontiers in virology\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-02-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in virology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fviro.2024.1358963\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in virology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fviro.2024.1358963","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景肠道病毒D68(EV-D68)主要引起呼吸道感染,偶尔表现为神经系统症状。方法对2012-2022年期间奥斯陆大学医院接收的14岁以下儿童的呼吸道样本进行了EV-D68检测。使用半特异性 RT-PCR 对 2012-2015 年的样本进行了回顾性筛查,并通过 EV-D68 特异性 RT-PCR 对阳性样本进行了确认。结果在检测的 22911 份样本中,有 338 份样本(324 名患者)检测到了 EV-D68。大多数 EV-D68 病例发生在 8 月至 12 月。2014 年、2016 年和 2022 年的检出率最高(占 8 月至 12 月样本的 6.0%、7.8% 和 6.6%)。2018 年和 2019 年(1.0% 和 2.4%)以及 2014 年疫情爆发前几年(2012 年:1.3%,2013 年:0.8%)的检出率较低。2020-2021 年发现的病例很少。在 EV-D68 阳性患者中,0-1 岁儿童占 40%,0-4 岁儿童占 78%。大多数EV-D68患者(83%)都住院治疗。除2018年和COVID-19限制期间(2020-2021年)发病率较低外,检出率各不相同,呈两年一爆发的趋势。由于 EV-D68 有可能导致严重的呼吸道疾病和重大的神经系统并发症,因此进行 EV-D68 检测对于诊断临床疑似病例和监测疾病负担都至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Emergence of enterovirus D68 in a Norwegian paediatric population 2012-2022
Background

Enterovirus D68 (EV-D68) primarily causes respiratory infection, occasionally manifesting with neurological symptoms. Outbreak reports have been published from various countries including Norway, but a longitudinal study on EV-D68 prevalence in Northern Europe is lacking.

Methods

Respiratory samples from children ≤14 years received at Oslo University Hospital in the years 2012-2022 were examined for EV-D68. Samples from 2012-2015 were retrospectively screened using a semi-specific RT-PCR, with positive samples confirmed by an EV-D68 specific RT-PCR. Samples from 2016-2022 underwent routine diagnostics with the EV-D68 specific RT-PCR.

Results

Among the 22,911 samples tested, EV-D68 was detected in 338 samples (324 patients). Most EV-D68 cases occurred in August to December. The highest detection rate was recorded in 2014, 2016 and 2022 (6.0%, 7.8% and 6.6% of samples from August-December). Lower frequencies were observed in 2018 and 2019 (1.0% and 2.4%), and in the years before the 2014 outbreak (2012: 1.3%, 2013: 0.8%). Few cases were identified in 2020-2021. Children aged 0-1 years accounted for 40%, and 0-4 years for 78%, of the EV-D68 positive patients. Most of the patients with EV-D68 (83%) were hospitalised.

Discussion

Also in Norway, EV-D68 has caused outbreaks with significant disease burden, especially among the youngest children. The detection rate varies, with a trend towards biennial outbreaks, except for low numbers in 2018 and during the COVID-19 restrictions (2020-2021). Due to its potential for severe respiratory illness and significant neurological complications, conducting EV-D68 testing is essential both for diagnosing clinically suspected cases, and for monitoring the disease burden.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信